Results 51 to 60 of about 10,614 (201)

Síndrome de Evans: reporte de un caso [PDF]

open access: yes, 2014
El Síndrome de Evans es un trastorno inmunológico atípico y poco frecuente causado por anticuerpos contra antígeno de membrana, de hematíes y plaquetas cursando con manifestaciones hemorrágicas en piel y mucosas generalmente de evolución no siempre ...
Alarcón Martínez, Yanet   +3 more
core   +1 more source

Routine Cord Blood Platelet Counts and Potential for Severe Neonatal Alloimmune Thrombocytopaenia (NAIT): A Cohort Study of 12 Yr. Experience at Middlemore Hospital, New Zealand

open access: yesAustralian and New Zealand Journal of Obstetrics and Gynaecology, Volume 66, Issue 1, February 2026.
ABSTRACT Background Neonatal alloimmune thrombocytopaenia (NAIT) is a rare but potentially serious condition where maternal antibodies result in destruction of foetal and neonatal platelets. At Middlemore Hospital in south Auckland, routine cord blood platelet counts were performed over many years.
Galama Vela   +2 more
wiley   +1 more source

IDIOPATHIC THROMBOCYTOPENIC PURPURA (i.T.P.) [PDF]

open access: yesActa Medica Iranica, 1987
The course of t he disorder is acute and chronic.The acute form o f the disease occurs most c ommonly in children , but is seen i n adults as well . The chronic recurrent f orm occurs most o f t e n in women between t wenty and forty years of age.
Sh. MOHAMEDI M ZAMANIANPOUR ML GHASEMI
doaj   +1 more source

New‐onset autoimmune disease following SARS‐CoV‐2 infection and mRNA vaccination in Norway: A retrospective cohort study

open access: yesJournal of Internal Medicine, Volume 299, Issue 2, Page 271-282, February 2026.
Abstract Background Studies suggest an increase in autoimmune diseases following SARS‐CoV‐2 infection and/or COVID‐19‐vaccination. We aimed to describe possible associations in Norway. Methods We used information from the emergency preparedness register for COVID‐19, BeredtC19, for all residents aged 18–64 (N = 3,450,080).
Håkon Bøås   +4 more
wiley   +1 more source

Causal relationship between immune cells and idiopathic thrombocytopenic purpura: A bidirectional Mendelian randomization study

open access: yes
Rheumatology &Autoimmunity, EarlyView.
Heyi Zhang   +9 more
wiley   +1 more source

European Code Against Cancer, 5th edition – cancer‐causing infections and related interventions

open access: yesMolecular Oncology, Volume 20, Issue 1, Page 96-116, January 2026.
The 5th edition of the European Code Against Cancer (ECAC5) contains 14 recommendations on cancer prevention. Here, we update the cancer prevention recommendations related to cancer‐causing infections, namely H. pylori, HPV, HBV, HCV and HIV, positioned as recommendation number 12.
Catharina Johanna Alberts   +18 more
wiley   +1 more source

Occurrence of immune thrombocytopenic purpura in a patient with essential thrombocythemia: How the immune system can overcome a neoplastic clone

open access: yesClinical Case Reports, 2020
Our case highlights the possible coexistence of essential thrombocythemia (ET) and idiopathic thrombocytopenic purpura (ITP), two pathological entities with opposite clinical and laboratory manifestations.
Antonio Carruale   +5 more
doaj   +1 more source

Púrpura Trombocitopénica Idiopática y sangramiento gingival. Presentación de un caso. [PDF]

open access: yes, 2012
Se realiza la presentación de un caso de una paciente con antecedentes de púrpura trombocitopénica idiopática por defecto en el factor F3p de la coagulación, que acudió a la consulta de Periodoncia porque presentaba sangramiento de las encías.
Grisel Isabel Echenagusía López   +2 more
core   +1 more source

Immune‐Mediated Thrombocytopenia in an Ulcerative Colitis Patient After Initiating Filgotinib Treatment: A Case Report

open access: yesClinical Case Reports, Volume 14, Issue 1, January 2026.
Timeline of events ABSTRACT Moderate‐to‐severe ulcerative colitis can be effectively treated with JAK‐1 inhibition, but platelet counts should be closely monitored, especially in active disease. We confirmed immune‐mediated thrombocytopenia (ITP) in one of our patients after the initiation of filgotinib. Whether this was drug‐induced is uncertain.
M. J. van der Hoff   +2 more
wiley   +1 more source

Hemostatic changes by thrombopoietin-receptor agonists in immune thrombocytopenia patients [PDF]

open access: yes, 2021
Thrombopoietin receptor agonist (TPO-RA) treatment increases the thrombosis rate in immune thrombocytopenia (ITP). We hypothesize that TPO-RAs influence platelet function, global and secondary hemostasis and/or fibrinolysis.
Brandwijk, Odila N   +5 more
core  

Home - About - Disclaimer - Privacy